Article
Gastroenterology & Hepatology
Tai-Chung Tseng, Chieh Chiang, Chun-Jen Liu, Chun-Ming Hong, Tung-Hung Su, Hung-Chih Yang, Wan-Ting Yang, Chen-Hua Liu, Pei-Jer Chen, Jia-Horng Kao
Summary: This study aimed to explore the association between spontaneous seroclearance of hepatitis B surface antigen (HBsAg) and hepatitis B core-related antigen (HBcrAg) levels. The results showed that lower HBcrAg levels were associated with an increased likelihood of HBsAg seroclearance. Especially for patients with HBsAg levels >1000 IU/mL, HBcrAg levels <10,000 U/mL served as an independent predictor for HBsAg seroclearance.
Article
Gastroenterology & Hepatology
Sammy Saab, Nguyen Pham, William Wu, Long Dang, An Dang, Jung Yum, Kisub Shim, Steven Wu
Summary: There is a potential clinical association between HBsAg seroclearance and the severity of liver fibrosis in patients with chronic hepatitis B virus infection. Spontaneous HBsAg seroclearance remains rare in these patients.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Gastroenterology & Hepatology
Hyun Yang, Si Hyun Bae, Heechul Nam, Hae Lim Lee, Sung Won Lee, Sun Hong Yoo, Myeong Jun Song, Jung Hyun Kwon, Soon Woo Nam, Jong Young Choi, Seung Kew Yoon, Jeong Won Jang
Summary: After HBsAg seroclearance, there is still a risk of developing hepatocellular carcinoma (HCC). Age, cirrhosis, family history, and more-than-moderate alcohol consumption are independent factors predictive of HCC. The novel prediction model based on these four variables allows reliable risk estimation of HCC after HBsAg seroclearance.
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Ka Shing Cheung, Lung Yi Mak, Lok Ka Lam, James Fung, Fen Liu, Wai Kay Seto, Man Fung Yuen
Summary: Patients with HBsAg seroclearance have favorable long-term survival. However, liver-related adverse outcomes still develop, necessitating further investigations on beneficial effects of statins.
HEPATOLOGY INTERNATIONAL
(2021)
Article
Microbiology
Michele Barone, Andrea Iannone, Martino Mezzapesa, Michele Milella, Francesco Di Gennaro, Grazia Niro, Rosa Cotugno, Raffaele Cozzolongo, Giuseppe Mennea, Maria Rendina, Alfredo Di Leo
Summary: This study evaluated spontaneous HBsAg seroclearance and its associated factors and disease progression in HBeAg-negative patients with inactive infection in South Italy for the first time. The study found that patients with HBsAg levels <100 IU/mL had the highest probability of HBsAg seroclearance.
Article
Gastroenterology & Hepatology
Sun Yoo, Ji Yoon Kim, Young-Suk Lim, Seungbong Han, Jonggi Choi
Summary: HBsAg seroclearance is associated with a lower risk of late recurrence of HBV-related HCC among Korean patients who undergo curative liver resection.
JOURNAL OF HEPATOLOGY
(2022)
Article
Endocrinology & Metabolism
Evie van der Spoel, Nicolien A. van Vliet, Rosalinde K. E. Poortvliet, Robert S. Du Puy, Wendy P. J. den Elzen, Terence J. Quinn, David J. Stott, Naveed Sattar, Patricia M. Kearney, Manuel R. Blum, Heba Alwan, Nicolas Rodondi, Tinh-Hai Collet, Rudi G. J. Westendorp, Bart E. Ballieux, J. Wouter Jukema, Olaf M. Dekkers, Jacobijn Gussekloo, Simon P. Mooijaart, Diana van Heemst
Summary: This study aims to investigate the incidence and determinants of spontaneous normalization of TSH levels in older adults with subclinical hypothyroidism. The study found that younger age, female sex, lower initial TSH level, higher initial free T4 level, absence of thyroid peroxidase antibodies, and a follow-up measurement in summer were independent determinants for TSH level normalization.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Virology
Takanori Suzuki, Kentaro Matsuura, Takehisa Watanabe, Takeshi Matsui, Shintaro Ogawa, Hayato Kawamura, Kayoko Kuno, Kei Fujiwara, Shunsuke Nojiri, Hiromi Kataoka, Yasuhito Tanaka
Summary: Two novel assays, iTACT-HBcrAg and iTACT-HBsAg, have been developed to investigate the longitudinal profiles of these antigens in HBsAg seroclearance patients. The presence of HBcrAg may contribute to the progression of chronic hepatitis B.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Immunology
Peipei Wang, Zhishuo Mo, Ying Zhang, Chunxia Guo, Trevor Kudzai Chikede, Dabiao Chen, Ziying Lei, Zhiliang Gao, Qian Zhang, Qiaoxia Tong
Summary: This study investigates the changes in cytokines during nucleos(t)ide analogues and peginterferon-alpha therapy and their impact on the HBsAg serologic response. It found that IL-5 may be used as a biomarker for HBsAg seroclearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon-alpha. This finding helps to develop a better understanding of the immune pathogenesis of chronic HBV infection.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Jie Li, Hwai- Yang, Ming-Lun Yeh, Michael H. Le, An K. Le, Yee Hui Yeo, Chia-Yen Dai, Scott Barnett, Jian Q. Zhang, Jee-Fu Huang, Huy N. Trinh, Christopher Wong, Clifford Wong, Joseph K. Hoang, Ramsey Cheung, Ming-Lung Yu, Mindie H. Nguyen
Summary: This study found that concurrent FL in patients with CHB significantly reduces the risk of cirrhosis and HCC, as well as increases the rate of HBsAg seroclearance. Further research is needed to confirm these findings and investigate the underlying mechanisms of FL on CHB.
JOURNAL OF INFECTIOUS DISEASES
(2021)
Article
Gastroenterology & Hepatology
Jonggi Choi, Sun Yoo, Young-Suk Lim
Summary: The study found that the risks of HCC and clinical events were not significantly different between spontaneous and NUC-induced HBsAg seroclearance. However, even after HBsAg seroclearance, the annual risk of HCC exceeds the recommended cutoff for HCC surveillance, suggesting continued monitoring is necessary.
Article
Virology
Dan-Yi Zeng, Zhan Chen, Mei-Zhu Hong, Ling-Ping Jiang, Xiao-Ning Chen, Han-Xin Xue, Jin-Shui Pan, Yueyong Zhu
Summary: Traditional Chinese medicine can be used as an adjuvant or alternative therapy for chronic hepatitis B, and may have a role in HBsAg seroclearance through mechanisms such as M1 polarization of macrophages and changes in the gut microbiota.
JOURNAL OF MEDICAL VIROLOGY
(2023)
Article
Gastroenterology & Hepatology
Fumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, Hitomi Sezaki, Norio Akuta, Shunichiro Fujiyama, Yusuke Kawamura, Satoshi Saitoh, Yasuji Arase, Mariko Kobayashi, Hiromitsu Kumada
Summary: Patients with chronic hepatitis B (CHB) who achieved HBsAg seroclearance after nucleos(t)ide analog (NA) therapy rarely experienced virological or clinical relapse after treatment cessation.
JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Pharmacology & Pharmacy
Xiu-Qing Pang, Xing Li, Wei-Hang Zhu, Run-Kai Huang, Zhi-shuo Mo, Ze-Xuan Huang, Yuan Zhang, Dong-Ying Xie, Zhi-Liang Gao
Summary: This study investigated the role of erythroid progenitor cells (EPCs) in HBsAg seroclearance following pegylated interferon-alpha (PEG-IFN) treatment. The findings suggest that CD45+EPCs inhibit T cell activation and suppress HBV-specific CD8+T cells, which can be overcome by anti-LAG3 and anti-TGF-beta combination treatment.
ANTIVIRAL RESEARCH
(2023)
Article
Multidisciplinary Sciences
Yu-Ju Chu, Hwai-I. Yang, Hui-Han Hu, Jessica Liu, Yu-Ling Lin, Chia-Ling Chang, Wen-Sheng Luo, Chin-Lan Jen, Chien-Jen Chen
Summary: This study found an association between HLA genetic variants and HBV genotype with HBsAg seroclearance and longitudinal HBsAg serodecline. The results suggest that both the spontaneous clearance and decline of HBsAg levels are influenced by the interaction between HLA variants and HBV genotype.
SCIENTIFIC REPORTS
(2023)
Article
Gastroenterology & Hepatology
Homie Razavi, Sarah Blach, Devin Razavi-Shearers, Faisal Abaalkhail, Zaigham Abbas, Ayat Abdallah, Paulo Abrao Ferreira, Laith Jamal Abu Raddad, Danjuma Adda, Kosh Agarwal, Alessio Aghemo, Aijaz Ahmed, Said A. Al-Busafi, Waleed Al-hamoudi, Saad Al-Kaabi, Hamad Al-Romaihi, Badr Aljarallah, Khalid AlNaamani, Saleh Alqahtani, Khalid Alswat, Ibrahim Altraif, Tarik Asselah, Bruce Bacon, Fernando Bessone, Abdul Rahman Bizri, Tim Block, Ferruccio Bonino, Carlos Eduardo BranclaoMello, Kimberly Browny, Philip Bruggmann, Maurizia Rossana Brunetto, Maria Buti, Joaquin Cabezas, Jose Luis Calleja, Erika Castro Batanjer, Henry Lik-Yuen Chan, Henry Chang, Chien-Jen Chen, Peer Brehm Christensen, Wan-Long Chuang, Laura Cisneros, Chari Cohen, Massimo Colombo, Brian Conway, Curtis Cooper, Antonio Craxi, Javier Crespo, Esther Croes, Donna Cryer, Fernando Passos Cupertino de Barros, Moutaz Derbala, John Dillon, Wahid Doss, Xiaoguang Dou, Joseph Doyle, Ann-Sofi Duberg, Ellen Dugan, Rick Dunn, Geoffrey Dusheiko, Hisham El Khayat, Manal H. EI-Sayed, Ahad Eshraghian, Gamal Esmat, Rafael Esteban Mur, Sameera Ezzat, Karolin Falconer, Eduardo Fassio, Paulo Ferrinho, Steven Flamm, Robert Flisiak, Graham Foster, James Fung, Javier Garcia-Samaniego, Robert G. Gish, Fernando Goncales, Waldemar Halota, Waseem Hamoudi, Mohamed Hassany, Angelos Hatzakis, Susan Hay, Sayed Himatt, I. M. Hoepelman, Yao-Chun Hsu, Yee Tak Hui, Bela Hunyady, Ira Jacobson, Naveed Janjua, Harry Janssen, Peter Jarcuska, Kenneth Kabagambe, Tatsuya Kanto, Jia-Horng Kao, Sabahattin Kaymakoglu, David Kershenobich, Faryal Khamis, Dong Joon Kim, Young Kim, Loreta A. Kondili, Shyamasundaran KottiliI, Anna Kramvis, Marcelo Kugelmas, Masayuki Kurosaki, Karine Lacombe, Martin Lagging, WaiCheung Lao, Daniel Lavanchy, Jeffrey Lazarus, Alice Lee, Samual S. Lee, Miriam Levyl, Valentina Liakina, YoungSuk Lim, Shuang Liu, Willis Maddrey, Reza Malekzade, Rui Tato Marinho, Poonam Mathur, Mojca Maticic, Maria Cassia Mendes Correa, Jorge Mera, Shahin Merat, Sherif Mogawer, Rosmawati Mohamed, Beat Muellhaupti, David Muljono, Ibrahim Mostafa, Mendez Sanchez Nahum, Arif Nawaz, Francesco Negro, Michael Ninburg, Qing Ning, Boatemaa Ntiri-Reid, Pagbajabyn Nymadawa, Anne Oevrehus, Necati Ormeci, Mauricio Orrego, Alaa Osman, Tsendsuren Oyunsuren, Calvin Pant, Vassiliki Papaevangelou, George Papatheodoridis, Stephanie Popping, Papu Prasad, Rittoo Prithiviputh, Huma Qureshi, Alnoor Ramji, Kathryn Razavi-Shearer, Rajender Reddy, William Remak, Clemens Richter, Ezequiel Ridruejo, Geert Robaeys, Stuart Robert, Lewis Roberts, Francoise Roudot-Thoraval, Sammy Saab, Sanaa Said, Amjad Salamat, Faisal Sanai, Juan Francisco Sanchez-Avila, Eugene Schiff, Raymond Schinazi, Giada Sebastiani, Carole Seguin-Devaux, R. P. Shanmugam, Ala Sharara, Sonjelle Shilton, Daniel Shouval, William Sievert, Marieta Simonova, Amir Ali Sohrabpour, Mark Sonderup, Alejandro Soza, C. Wendy Spearman, Nancy Steinfurth, Mark Sulkowski, Soek-Siam Tan, Junko Tanaka, Dhondup Tashi, Hla-Hla Thein, Peyton Thompson, Ieva Tolmane, Mehlika Toy, Jonas Valantinas, David Van de Vijver, Patricia Velez-Moller, Adriana Vince, Imam Waked, Su Wang, Heiner Wedemeyer, Vincent Wong, Qing Xie, Seiji Yamada, Hwai- Yang, Kakharman Yesmembetov, Yusuf Yilmaz, Zobair Younossi, Ming-Lung Yu, Man-Fung Yuen, Cihan Yurdaydin, Aasim Yusuf, Amany Zekry, Stefan Zeuzem
Summary: The 69th World Health Assembly endorsed the goal to eliminate hepatitis infection as a public health threat by 2030, followed by global targets for the care and management of hepatitis B and hepatitis C infections. However, tracking countries' progress towards these elimination goals revealed limitations of existing targets and recommended changes to simplify and adjust the targets for better impact and recognition of countries' efforts.
JOURNAL OF VIRAL HEPATITIS
(2021)
Article
Gastroenterology & Hepatology
Jiyoon Park, An K. Le, Tai-Chung Tseng, Ming-Lun Yeh, Dae Won Jun, Huy Trinh, Grace L. H. Wong, Chien-Hung Chen, Cheng-Yuan Peng, Sung Eun Kim, Hyunwoo Oh, Min-Sun Kwak, Ka Shing Cheung, Hidenori Toyoda, Yao-Chun Hsu, Jae Yoon Jeong, Eileen L. Yoon, Teerapat Ungtrakul, Jian Zhang, Qing Xie, Sang Bong Ahn, Masaru Enomoto, Jae-Jun Shim, Chris Cunningham, Soung Won Jeong, Yong Kyun Cho, Eiichi Ogawa, Rui Huang, Dong-Hyun Lee, Hirokazu Takahashi, Pei-Chien Tsai, Chung-Feng Huang, Chia-Yen Dai, Cheng-Hao Tseng, Satoshi Yasuda, Ritsuzo Kozuka, Jiayi Li, Christopher Wong, Clifford C. Wong, Changqing Zhao, Joseph Hoang, Yuichiro Eguchi, Chao Wu, Yasuhito Tanaka, Ed Gane, Tawesak Tanwandee, Ramsey Cheung, Man-Fung Yuen, Hyo-Suk Lee, Ming-Lung Yu, Jia-Horng Kao, Hwai-I Yang, Mindie H. Nguyen
Summary: This study aimed to determine the rates of cirrhosis and hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB), stratified by age, sex, treatment status, and disease activity. The results show that there is significant variability in CHB disease progression rates even among lower-risk populations.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hui-Han Hu, Wen-Juei Jeng, Mei-Hung Pan, Wun-Sheng Luo, Chia-Ling Chang, Yen-Tsung Huang, Chien-Yu Su, Chen-Tse Chiang, Chin-Lan Jen, Yu-Chuan Chien, Shen-Nan Lu, Li-Yu Wang, Li-Rung Huang, Mei-Hsuan Lee, Jessica Liu, Mindie H. Nguyen, Chien-Jen Chen, Hwai- Yang
Summary: sPD-1 level is a novel marker that predicts spontaneous HBsAg seroclearance in patients with HBeAg-negative chronic hepatitis B with undetectable HBV DNA.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Public, Environmental & Occupational Health
An-Shun Tai, Yen-Tsung Huang, Hwai- Yang, Lauren V. Lan, Sheng-Hsuan Lin
Summary: Regression-based approaches are commonly used in causal mediation analysis, but they may not be efficient in cases with multiple mediators. Therefore, a flexible simulation-based approach was developed to address estimation issues and increase flexibility in model selection. The method was evaluated using a Taiwanese Cohort Study dataset and showed promising results in investigating the mediating role of HBV viral load in the effect of HCV infection on hepatocellular carcinoma.
FRONTIERS IN PUBLIC HEALTH
(2022)
Letter
Gastroenterology & Hepatology
Wen-Juei Jeng, Mei-Hung Pan, Hwai- Yang
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Gastroenterology & Hepatology
Yu-Ju Chu, Wen-Juei Jeng, Mei-Hung Pan, Hui-Han Hu, Wen-Sheng Luo, Chien-Yu Su, Chen-Tse Chiang, Chin-Lan Jen, Chien-Jen Chen, Hwai- Yang
Summary: Serum sPD-1 levels may serve as a novel immunological predictor for spontaneous HBeAg seroclearance in patients with chronic hepatitis B. Lower baseline sPD-1 levels and long-term decline in sPD-1 levels were independent predictors for HBeAg seroclearance, particularly significant in patients with genotype C infection.
JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Virology
Wen-Juei Jeng, Chien-Hung Chen, Yi-Wen Wang, Mei-Hung Pan, Chia-Wei Lin, Chun-Yen Lin, Hwai- Yang
Summary: There is no correlation between sPD-1 levels measured by MyBioSource (MB) and R&D (RD) kits. The sPD-1 measured by MB showed strong correlations with HBsAg, HBV DNA, and ALT levels, while an opposite trend was seen with the RD kit. Multivariate linear regression analysis indicated that HBsAg and ALT levels were the major factors associated with sPD-1 levels measured by MB and RD, respectively.
Article
Gastroenterology & Hepatology
Shanshan Wu, Jialing Zhou, Xiaoning Wu, Yameng Sun, Bingqiong Wang, Yuanyuan Kong, Siyan Zhan, Jidong Jia, Hwai- Yang, Hong You
Summary: This study assessed the comparative performance of 14 hepatocellular carcinoma prediction models in chronic hepatitis B patients and found that several models performed best when using on-treatment values within the first 2 years.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2022)
Article
Gastroenterology & Hepatology
Yi-Chung Hsieh, Mei-Hung Pan, Wen-Juei Jeng, Hui-Han Hu, Jessica Liu, Masashi Mizokami, Chien-Jen Chen, Hwai- Yang
Summary: The study found an association between hepatitis B core-related antigen (HBcrAg) and hepatocellular carcinoma (HCC) in chronic hepatitis B patients. The relationship between HBcrAg and HCC was also investigated in individuals seronegative for hepatitis B surface antigen and anti-hepatitis C virus (NBNC) in Taiwan. The results showed that HBcrAg positivity was significantly associated with higher risk of HCC, indicating that it might serve as a marker for identifying individuals at a higher risk of HCC in hepatitis B virus endemic areas.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Chien-Wei Peng, Wen-Juei Jeng, Hwai- Yang, Yen-Chun Liu, Rong-Nan Chien, Yun-Fan Liaw
Summary: In HBeAg negative chronic hepatitis B (CHB) patients, stopping tenofovir and other nucleos(t)ide analogues (Nucs) is associated with more frequent and severe clinical relapse. This study found that switching to entecavir more than 12 weeks prior to stopping treatment can delay and reduce the occurrence of clinical relapse and flares.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
(2022)
Article
Oncology
Ilona Argirion, Jalen Brown, Sarah Jackson, Ruth M. Pfeiffer, Tram Kim Lam, Thomas R. O'Brien, Kelly J. Yu, Katherine A. McGlynn, Jessica L. Petrick, Ligia A. Pinto, Chien-Jen Chen, Allan Hildesheim, Hwai- Yang, Mei-Hsuan Lee, Jill Koshiol
Summary: This study investigated the role of circulating immunologic markers in predicting the progression of liver disease in individuals chronically infected with hepatitis C virus (HCV). The findings suggest that these markers play an important role in predicting HCV-related cirrhosis even 11 years after enrollment.
Meeting Abstract
Gastroenterology & Hepatology
Rachel Wen-Juei Jeng, Chien-Hung Chen, Hwai-I Yang, Yi-Cheng Chen, Yen-Chun Liu, Chia-Ying Wu, Rong-Nan Chien, Yun-Fan Liaw
JOURNAL OF HEPATOLOGY
(2022)
Meeting Abstract
Gastroenterology & Hepatology
Rachel Wen-Juei Jeng, Yu-Ju Chu, Mei-Hung Pan, Hui-Han Hu, Wun-Sheng Luo, Chien-Yu Su, Chen-Tse Chiang, Chin-Lan Jen, Sheng-Nan Lu, Li-Yu Wang, Chien-Jen Chen, Hwai-I Yang
JOURNAL OF HEPATOLOGY
(2022)
Article
Gastroenterology & Hepatology
Hui-Chen Wu, Wen-Juei Jeng, Mei-Hung Pan, Yi-Chung Hsieh, Sheng-Nan Lu, Chien-Jen Chen, Hwai- Yang
Summary: This study examined the cumulative risk of hepatocellular carcinoma (HCC) and mortality from liver-related disease among a non-hepatitis virus-infected population. It found that modifiable risk factors such as alcohol consumption, heart disease, diabetes, and abnormal liver function tests were strongly associated with an increased risk of HCC and mortality.
Article
Medicine, Research & Experimental
Tsung-Yu Tsai, Ming-Ting Huang, Pei-Shan Sung, Cheng-Yuan Peng, Mi-Hua Tao, Hwai-I Yang, Wei-Chiao Chang, An-Suei Yang, Chung-Ming Yu, Ya-Ping Lin, Ching-Yu Bau, Chih-Jen Huang, Mei-Hung Pan, Chung-Yi Wu, Chwan-Deng Hsiao, Yi-Hung Yeh, Shiteng Duan, James C. Paulson, Shie-Liang Hsieh
Summary: Chronic hepatitis B infection is difficult to eliminate with current antiviral medications. Research shows that a specific antigen in HBV can induce immunosuppression by binding to SIGLEC-3, and certain genetic variations may increase the risk of hepatocellular carcinoma in CHB patients. Blocking SIGLEC-3 could potentially reactivate host immunity to HBV and reduce the incidence of HCC in this patient population.
JOURNAL OF CLINICAL INVESTIGATION
(2021)